NOT-HL-15-255: Notice of National Heart, Lung, and Blood Institute (NHLBI) Participation in PA-15-028 "Research on Eosinophil Associated Disorders (R21)"

Notice of National Heart, Lung, and Blood Institute (NHLBI) Participation in PA-15-028 "Research on Eosinophil Associated Disorders (R21)"

Notice Number: NOT-HL-15-255

Key Dates
Release Date: March 17, 2015

Related Announcements
PA-15-028

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in PA-15-028 "Research on Eosinophil Associated Disorders (R21)".

The following sections of PA-15-028 have been updated to reflect NHLBI's participation in this funding opportunity announcement.

Part 1. Overview Information

Components of Participating Organizations
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Heart, Lung, and Blood Institute (NHLBI)

Catalog of Federal Domestic Assistance (CFDA) Numbers
93.855, 93.856, 93.847, 93.846, 93.837, 93.838, 93.839, 93.233

Section VII. Agency Contacts

Scientific/Research Contact(s)
Patricia Noel, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0202
Email: [email protected]

Financial/Grants Management Contact(s)
Howard Moore
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-5081
Email: [email protected]

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Patricia Noel, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0202
Email: [email protected]